CMS cannot finalize policies that were not, in some way, shape, or form, included in the proposed reg. While CMS can ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully understanding the various factors affecting ...

Reports Q4 revenue $64.3M, consensus $57.4M. “LifeMD (LFMD) had a great fourth quarter. We not only achieved record quarterly revenue and ...

Q4 2024 Results Conference Call March 10, 2025 4:30 PM ETCompany ParticipantsJustin Schreiber - Chairman and Chief ...

Thank you for joining us to discuss LifeMD Inc fourth-quarter and full-year 2024 earnings results. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, ...

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%Adjusted EBITDA increased 78% to $9.0 ...

Medicare’s block on obesity medication coverage ... like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), which generally have to be paid for out-of-pocket as ...

Eli Lily's GLP-1 competitor Mounjaro/Zepbound doesn't make the list ... Inflation Reduction Act is lowering prices for people on Medicare. HHS will continue negotiating in the best interest ...

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...